Document Detail


Esmolol: a review of its use in the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension.
MedLine Citation:
PMID:  22191799     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Supraventricular tachyarrhythmia (including atrial fibrillation), hypertension and tachycardia in the perioperative setting, and acute ischaemic heart disease are generally agreed to require rapid attention and treatment. Prolonged tachyarrhythmia or hypertension can result in significant morbidity, such as cerebrovascular events, myocardial infarction and other end-organ damage. This article reviews the clinical efficacy and tolerability of intravenous infusions of esmolol for the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension, and provides an overview of the pharmacological properties of the drug. Esmolol, a cardioselective β-blocker, has been proven effective in the control of elevated haemodynamic parameters in patients with supraventricular tachyarrhythmia, hypertension and tachycardia in the perioperative setting, and acute ischaemic heart disease, as well as being associated with a reduced risk of some clinical sequelae to increased haemodynamic parameters. Esmolol is, moreover, generally well tolerated; while it is associated with an increased risk of hypotension, this is rapidly reversible. Definitive conclusions on the efficacy of esmolol are difficult to reach, as most trials investigating esmolol have limitations such as small patient populations, and few studies investigate the same parameters. Ideally, several further studies would be beneficial; however, as esmolol is a well established, older drug, these are less likely to occur. Despite this, esmolol, as a fast-acting, rapidly reversible, easily titratable β-blocker, is an established option for the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension.
Authors:
Karly P Garnock-Jones
Related Documents :
16814669 - Post-reperfusion myocardial infarction: long-term survival improvement using adenosine ...
12403659 - Scores for post-myocardial infarction risk stratification in the community.
17085939 - Effects of metoprolol on sympathetic remodeling and electrical remodeling at infarcted ...
14973349 - Prognostic importance of predischarged troponin t levels in acute anterior myocardial i...
19641679 - Reduction in oxidative stress and modulation of heart failure subsequent to myocardial ...
17563049 - Multidisciplinary team for enhancing care for patients with acute myocardial infarction...
21327539 - Ginsenoside-rg1 enhances angiogenesis and ameliorates ventricular remodeling in a rat m...
1157819 - Metabolic and structural recovery of left ventricular canine myocardium from regional c...
2026469 - Hypermagnesemia following aluminum phosphide poisoning.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Drugs     Volume:  72     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2011-12-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  109-32     Citation Subset:  IM    
Affiliation:
Adis, a Wolters Kluwer Business, Auckland, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Crizotinib: in locally advanced or metastatic non-small cell lung cancer.
Next Document:  Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder.